Search Within

Elaine Mary Walsh

Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
  3. Book Section (1)
  4. Review (1)
Groups
  1. Breast Medicine Service (6)
  2. Department of Medicine (6)
  3. Solid Tumor Oncology Division (6)
  4. Survivorship Research (5)
  5. Population Sciences Research Program (4)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)

More Groups

People
  1. Mark Robson (3)
  2. Komal Jhaveri (2)
  3. Pedram Razavi (2)
  4. Sarat Chandarlapaty (2)
  5. Shanu Modi (2)
  6. Tiffany Traina (2)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (3)
  4. 2021 (1)
Publications
  1. Annals of Surgical Oncology (1)
  2. Breast Cancer Research and Treatment (1)
  3. Cancer Consult: Expertise in Clinical Practice. 2nd ed (1)
  4. Cancer Treatment Reviews (1)
  5. Clinical Breast Cancer (1)
  6. EMBO Molecular Medicine (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (2)
  2. Elsevier Inc. (2)
  3. Springer (2)
  4. Wiley Blackwell (2)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
    Journal Article

    Tai, Y.; Chow, A.; Han, S.; Coker, C.; Ma, W.; Gu, Y.; Estrada Navarro, V.; Kandpal, M.; Hibshoosh, H.; Kalinsky, K.; more...
    EMBO Molecular Medicine (2024)

    Fulltext@MSK | Save
  • Early-stage triple-negative breast cancer
    Book Section

    Traina, T. A.; dos Anjos, C.; Walsh, E.
    In Abutalib, S. A.; Markman, M.; Benson, A. B. 3rd; Rugo, H. S. (Eds.) Cancer Consult: Expertise in Clinical Practice. 2nd ed (2024)

    Fulltext@MSK | Save
  • BRCA mutational status is associated with higher rate of pathologic complete response in hormone receptor-positive breast cancer
    Meeting Abstract

    Myers, S. P.; Walsh, E. M.; Sevilimedu, V.; Barrio, A. V.; Tadros, A. B.; Mamtani, A.; Robson, M. E.; Morrow, M.; Lee, M. K.
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Meeting Abstract

    Drago, J. Z.; Pareja, F.; Jhaveri, K. L.; Walsh, E. M.; Ku, G. Y.; Maron, S. B.; Janjigian, Y. Y.; Robson, M. E.; Reis-Filho, J. S.; Modi, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: A feasibility study
    Journal Article

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Breast Cancer Research and Treatment (2022)

    Fulltext@MSK | Save
  • Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1/2 mutations or mutations in non-BRCA1/2, DNA damage repair genes
    Journal Article

    Walsh, E. M.; Mangini, N.; Fetting, J.; Armstrong, D.; Chan, I. S.; Connolly, R. M.; Fiallos, K.; Lehman, J.; Nunes, R.; Petry, D.; more...
    Clinical Breast Cancer (2022)

    Fulltext@MSK | Save
  • Accelerating drug development in breast cancer: New frontiers for ER inhibition
    Review

    Ferraro, E.; Walsh, E. M.; Tao, J. J.; Chandarlapaty, S.; Jhaveri, K.
    Cancer Treatment Reviews (2022)

    Fulltext@MSK | Save
  • Molecular tumor board guides successful treatment of a rare, locally aggressive, uterine mesenchymal neoplasm
    Journal Article

    Walsh, E. M.; Xing, D.; Lippitt, M. H.; Fader, A. N.; Wethington, S. L.; Meyer, C. F.; Gaillard, S. L.
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save